PubRank

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) (ORIGIN)

Clinical Trial ID NCT00069784

PubWeight™ 52.04‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00069784

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012 10.09
2 Diabetes and cancer: a consensus report. Diabetes Care 2010 6.71
3 n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012 6.16
4 The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care 2014 3.31
5 Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2007 3.12
6 Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J 2013 1.92
7 Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia. Circulation 2015 1.45
8 Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. Lancet Diabetes Endocrinol 2014 1.41
9 Characteristics associated with maintenance of mean A1C<6.5% in people with dysglycemia in the ORIGIN trial. Diabetes Care 2013 1.18
10 n-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes. Diabetes Care 2011 1.14
11 Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2014 1.05
12 Insulin therapy in critically ill patients. Vasc Health Risk Manag 2010 1.00
13 Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes. Diabet Med 2010 0.96
14 Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'. Diabetes Ther 2015 0.94
15 Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: a subanalysis of the ORIGIN trial. Int J Cardiol 2014 0.93
16 Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: an analysis of baseline data from the ORIGIN trial. Diabetes Care 2012 0.86
17 Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). Diabetes Care 2013 0.85
18 Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. Diabetologia 2014 0.84
19 IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy. Diabetes Ther 2015 0.83
20 Effects of polyunsaturated fatty acid consumption in diabetic nephropathy. Nat Rev Nephrol 2010 0.83
21 Omega-3 fatty acids and cognitive function in women. Womens Health (Lond Engl) 2010 0.83
22 Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial. Diabetes Care 2016 0.82
23 Risk Prediction for Early CKD in Type 2 Diabetes. Clin J Am Soc Nephrol 2015 0.82
24 Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials. Diabetes Ther 2016 0.77
25 Cost implications of the use of basal insulin glargine in people with early dysglycemia: the ORIGIN trial. J Diabetes Complications 2014 0.75
26 Use of Insulin Lispro Protamine Suspension in Pregnancy. Adv Ther 2015 0.75
27 Insulin glargine effectively achieves glycemic control and improves insulin resistance in patients with early type 2 diabetes that exhibit a high risk for cardiovascular disease. Exp Ther Med 2014 0.75
28 Clinical utility of insulin and insulin analogs. Islets 2013 0.75
29 Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function. Cardiovasc Diabetol 2016 0.75
30 Molecular mechanisms of hyperglycemia and cardiovascular-related events in critically ill patients: rationale for the clinical benefits of insulin therapy. Clin Epidemiol 2010 0.75
31 Strategies to detect abnormal glucose metabolism in people at high risk of cardiovascular disease from the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial population. J Diabetes 2011 0.75
Next 100